TR199902615T2 - Kortikosteroidlere verilen cevab�n mod�lasyonuna y�nelik metodlar ve kompozisyonlar. - Google Patents
Kortikosteroidlere verilen cevab�n mod�lasyonuna y�nelik metodlar ve kompozisyonlar.Info
- Publication number
- TR199902615T2 TR199902615T2 TR1999/02615T TR9902615T TR199902615T2 TR 199902615 T2 TR199902615 T2 TR 199902615T2 TR 1999/02615 T TR1999/02615 T TR 1999/02615T TR 9902615 T TR9902615 T TR 9902615T TR 199902615 T2 TR199902615 T2 TR 199902615T2
- Authority
- TR
- Turkey
- Prior art keywords
- agent
- response
- individual
- corticosteroids
- modulating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/820,692 US6054487A (en) | 1997-03-18 | 1997-03-18 | Methods and compositions for modulating responsiveness to corticosteroids |
| US1634698A | 1998-01-30 | 1998-01-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR199902615T2 true TR199902615T2 (xx) | 2000-03-21 |
Family
ID=26688484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR1999/02615T TR199902615T2 (xx) | 1997-03-18 | 1998-03-12 | Kortikosteroidlere verilen cevab�n mod�lasyonuna y�nelik metodlar ve kompozisyonlar. |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP0998300A1 (sl) |
| JP (1) | JP2002504091A (sl) |
| KR (1) | KR20000076420A (sl) |
| CN (1) | CN1269722A (sl) |
| AU (1) | AU734756B2 (sl) |
| BG (1) | BG103808A (sl) |
| BR (1) | BR9810409A (sl) |
| CA (1) | CA2282845A1 (sl) |
| DE (1) | DE998300T1 (sl) |
| ES (1) | ES2146192T1 (sl) |
| HU (1) | HUP0104439A3 (sl) |
| ID (1) | ID22975A (sl) |
| IL (1) | IL131815A0 (sl) |
| NO (1) | NO994506L (sl) |
| NZ (1) | NZ337769A (sl) |
| PL (1) | PL336464A1 (sl) |
| SI (1) | SI20110A (sl) |
| SK (1) | SK122199A3 (sl) |
| TR (1) | TR199902615T2 (sl) |
| WO (1) | WO1998041232A2 (sl) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6830751B1 (en) | 1994-03-14 | 2004-12-14 | Genetics Institute, Llc | Use of IL-12 antagonists in the treatment of rheumatoid arthritis |
| ZA95960B (en) * | 1994-03-14 | 1995-10-10 | Genetics Inst | Use of interleukin-12 antagonists in the treatment of autoimmune diseases |
| US7704944B2 (en) | 1997-08-14 | 2010-04-27 | Yeda Research And Development Company Ltd. | Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis |
| IL121860A0 (en) | 1997-08-14 | 1998-02-22 | Yeda Res & Dev | Interleukin-18 binding proteins their preparation and use |
| US7220717B2 (en) | 1997-08-14 | 2007-05-22 | Yeda Research And Development Company Ltd. | Interleukin-18 binding proteins, their preparation and use |
| US6184210B1 (en) | 1997-10-10 | 2001-02-06 | Cytovia, Inc. | Dipeptide apoptosis inhibitors and the use thereof |
| AR015966A1 (es) * | 1997-10-17 | 2001-05-30 | Smithkline Beecham Corp | Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito |
| DE69825976T2 (de) * | 1997-10-31 | 2005-09-01 | Wyeth | Verwendung von anti-il-12 antikörpern bei transplantationsabstossungen |
| EP1516630A3 (en) * | 1997-10-31 | 2006-05-03 | Wyeth | Use of anti-il-12 antibodies in transplantation rejection |
| WO1999025737A1 (en) * | 1997-11-19 | 1999-05-27 | Tanox Pharma B.V. | Compositions and methods for treatment of autoimmune diseases, using a monoclonal antibody to the interleukin-12 beta2-chain |
| AU755273B2 (en) * | 1998-03-16 | 2002-12-05 | Cytovia, Inc. | Dipeptide caspase inhibitors and the use thereof |
| CA2355345A1 (en) * | 1998-11-27 | 2001-06-28 | Technion Research & Development Foundation Ltd. | Interferon gamma inducing factor based vaccine and use of same for protective immunity against multiple sclerosis |
| JP3579355B2 (ja) * | 1998-12-09 | 2004-10-20 | プロテイン デザイン ラブス インコーポレイティド | ヒトの乾癬を予防及び治療するための乾癬モデル動物 |
| CA2367340A1 (en) | 1999-03-16 | 2000-09-21 | Cytovia, Inc. | Substituted 2-aminobenzamide caspase inhibitors and the use thereof |
| US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| US7883704B2 (en) | 1999-03-25 | 2011-02-08 | Abbott Gmbh & Co. Kg | Methods for inhibiting the activity of the P40 subunit of human IL-12 |
| DE19915465A1 (de) * | 1999-04-06 | 2000-10-19 | Apotech Res & Dev Ltd | Verwendung eines Caspase-Inhibitors zur Proliferationshemmung von Zellen und Verwendung eines oder mehrerer Caspase-Inhibitors/en zur Behandlung von Erkrankungen beruhend auf Lymphozyten-Hyperproliferation oder zur Suppression einer Immunantwort durch Lymphozyten |
| CA2369619A1 (en) | 1999-04-09 | 2000-10-19 | Cytovia, Inc. | Caspase inhibitors and the use thereof |
| IL131047A0 (en) * | 1999-07-22 | 2001-01-28 | Yeda Res & Dev | Use of il-18 inhibitors |
| JP2003508379A (ja) | 1999-08-27 | 2003-03-04 | サイトビア インコーポレイテッド | 置換α−ヒドロキシ酸カスパーゼインヒビターおよびその使用 |
| AU7127600A (en) * | 1999-09-17 | 2001-04-17 | Basf Aktiengesellschaft | Methods and compositions for modulating responsiveness to corticosteroids |
| US6566338B1 (en) | 1999-10-12 | 2003-05-20 | Cytovia, Inc. | Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death |
| TWI373343B (en) | 2000-02-10 | 2012-10-01 | Abbott Gmbh & Co Kg | Antibodies that bind human interleukin-18 and methods of making and using |
| ES2267778T3 (es) * | 2000-06-06 | 2007-03-16 | Glaxo Group Limited | Composicion para el tratamiento del cancer, que contiene un agente anti-neoplastico y un inhibidor de pde4. |
| WO2001097815A2 (de) * | 2000-06-22 | 2001-12-27 | Willy Ben Moussa Ben Mohammed | Verwendung von glukokortikosteroiden zur herstellung eines medikamentes für die behandlung von haarschwund |
| US20020025317A1 (en) * | 2000-07-20 | 2002-02-28 | Schering Ag | Bispecific monoclonal antibodies to IL-12 and IL-18 |
| WO2002022127A1 (en) * | 2000-09-13 | 2002-03-21 | Isis Innovation Limited | Use of phosphodiesterase inhibitors for the treatment of anorectal disorders |
| EP1199074A1 (en) * | 2000-09-15 | 2002-04-24 | Warner-Lambert Company | Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production |
| EP1188438A1 (en) * | 2000-09-15 | 2002-03-20 | Warner-Lambert Company | Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production |
| ME00549B (me) * | 2001-01-29 | 2011-10-10 | Serono Lab | Upotreba inhibitora il-18 za liječenje i/ili prevenciju srčanih oboljenja |
| EA009125B1 (ru) * | 2001-05-16 | 2007-10-26 | Йеда Рисерч Энд Дивелопмент Ко., Лтд. | Применение ингибиторов il-18 для лечения и/или предупреждения заболеваний, характерных для синдрома системной воспалительной реакции |
| NZ547695A (en) | 2001-06-26 | 2008-09-26 | Amgen Fremont Inc | Antibodies to OPGL |
| AR036741A1 (es) * | 2001-10-05 | 2004-09-29 | Combinatorx Inc | Combinaciones para el tratamiento de los trastornos inmunoinflamatorios |
| JP2003342196A (ja) * | 2002-05-31 | 2003-12-03 | Mukku:Kk | 静脈注射用組成物、その製造法およびその製剤 |
| TW200422042A (en) * | 2002-09-24 | 2004-11-01 | Combinatorx Inc | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
| WO2004028545A1 (en) * | 2002-09-25 | 2004-04-08 | Astrazeneca Ab | A COMBINATION OF A LONG-ACTING β2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES |
| US20060083714A1 (en) * | 2003-01-27 | 2006-04-20 | Warner James M | Combination of a pde iv inhibitor and a tnf-alpha antagonist |
| US20050100965A1 (en) | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
| JPWO2005110450A1 (ja) * | 2004-05-17 | 2008-03-21 | 学校法人慶應義塾 | 医薬組成物及び治療方法 |
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| US7887802B2 (en) | 2004-07-16 | 2011-02-15 | Atsuo Sekiyama | IL-18 receptor antagonist and pharmaceutical composition containing the antagonist |
| EP1810692A1 (en) * | 2004-10-13 | 2007-07-25 | Kyowa Hakko Kogyo Co., Ltd. | Remedies/preventives for chronic skin disease |
| CA2615173C (en) | 2005-07-14 | 2012-01-03 | Lipothera, Inc. | Sustained release enhanced lipolytic formulation for regional adipose tissue treatment |
| PL2077830T3 (pl) * | 2006-10-17 | 2013-04-30 | Lithera Inc | Sposoby, kompozycje i formulacje do leczenia orbitopatii tarczycowej |
| KR20150038227A (ko) | 2007-01-16 | 2015-04-08 | 애브비 인코포레이티드 | 건선의 치료방법 |
| WO2008121301A1 (en) | 2007-03-29 | 2008-10-09 | Abbott Laboratories | Crystalline anti-human il-12 antibodies |
| AU2009225797A1 (en) | 2008-03-18 | 2009-09-24 | Abbvie Inc. | Methods for treating psoriasis |
| US9132084B2 (en) | 2009-05-27 | 2015-09-15 | Neothetics, Inc. | Methods for administration and formulations for the treatment of regional adipose tissue |
| US9597531B2 (en) | 2010-11-24 | 2017-03-21 | Neothetics, Inc. | Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging |
| WO2015063669A1 (en) | 2013-10-30 | 2015-05-07 | Wockhardt Limited | Pharmaceutical compositions comprising combination of roflumilast and acebrophylline or pharmaceutically acceptable salts thereof |
| WO2023049809A1 (en) * | 2021-09-22 | 2023-03-30 | Iolyx Therapeutics, Inc. | Methods of treating ocular inflammatory diseases |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3320125A (en) * | 1964-04-28 | 1967-05-16 | Merck & Co Inc | Inhalation aerosol composition |
| DK0416950T3 (da) * | 1989-09-08 | 1993-10-11 | Glaxo Group Ltd | Medikamenter |
| IL104068A (en) * | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant |
| GB9202519D0 (en) * | 1992-02-06 | 1992-03-25 | Glaxo Group Ltd | Medicaments |
| MX9304585A (es) * | 1992-07-31 | 1994-03-31 | Glaxo Group Ltd | Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata. |
| GB9426252D0 (en) * | 1994-12-24 | 1995-02-22 | Glaxo Group Ltd | Pharmaceutical composition |
| US6149892A (en) * | 1995-04-14 | 2000-11-21 | Glaxowellcome, Inc. | Metered dose inhaler for beclomethasone dipropionate |
-
1998
- 1998-03-12 CA CA002282845A patent/CA2282845A1/en not_active Abandoned
- 1998-03-12 WO PCT/US1998/004916 patent/WO1998041232A2/en not_active Application Discontinuation
- 1998-03-12 SI SI9820032A patent/SI20110A/sl unknown
- 1998-03-12 HU HU0104439A patent/HUP0104439A3/hu unknown
- 1998-03-12 AU AU67604/98A patent/AU734756B2/en not_active Ceased
- 1998-03-12 TR TR1999/02615T patent/TR199902615T2/xx unknown
- 1998-03-12 KR KR1019997008524A patent/KR20000076420A/ko not_active Application Discontinuation
- 1998-03-12 BR BR9810409-8A patent/BR9810409A/pt not_active IP Right Cessation
- 1998-03-12 ES ES98912929T patent/ES2146192T1/es active Pending
- 1998-03-12 NZ NZ337769A patent/NZ337769A/xx unknown
- 1998-03-12 DE DE0998300T patent/DE998300T1/de active Pending
- 1998-03-12 JP JP54063398A patent/JP2002504091A/ja active Pending
- 1998-03-12 CN CN98805124A patent/CN1269722A/zh active Pending
- 1998-03-12 EP EP98912929A patent/EP0998300A1/en not_active Withdrawn
- 1998-03-12 ID IDW991185A patent/ID22975A/id unknown
- 1998-03-12 SK SK1221-99A patent/SK122199A3/sk unknown
- 1998-03-12 IL IL13181598A patent/IL131815A0/xx unknown
- 1998-03-12 PL PL98336464A patent/PL336464A1/xx unknown
-
1999
- 1999-09-17 NO NO994506A patent/NO994506L/no unknown
- 1999-10-13 BG BG103808A patent/BG103808A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU734756B2 (en) | 2001-06-21 |
| HUP0104439A3 (en) | 2002-08-28 |
| CA2282845A1 (en) | 1998-09-24 |
| NO994506L (no) | 1999-11-17 |
| ES2146192T1 (es) | 2000-08-01 |
| WO1998041232A2 (en) | 1998-09-24 |
| SK122199A3 (en) | 2000-12-11 |
| JP2002504091A (ja) | 2002-02-05 |
| BG103808A (en) | 2000-07-31 |
| KR20000076420A (ko) | 2000-12-26 |
| IL131815A0 (en) | 2001-03-19 |
| NO994506D0 (no) | 1999-09-17 |
| AU6760498A (en) | 1998-10-12 |
| ID22975A (id) | 1999-12-23 |
| BR9810409A (pt) | 2000-08-22 |
| SI20110A (sl) | 2000-06-30 |
| CN1269722A (zh) | 2000-10-11 |
| DE998300T1 (de) | 2001-03-01 |
| HUP0104439A2 (hu) | 2002-04-29 |
| EP0998300A1 (en) | 2000-05-10 |
| NZ337769A (en) | 2002-09-27 |
| WO1998041232A3 (en) | 2000-10-05 |
| PL336464A1 (en) | 2000-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR199902615T2 (xx) | Kortikosteroidlere verilen cevab�n mod�lasyonuna y�nelik metodlar ve kompozisyonlar. | |
| WO2001019373A3 (en) | Methods and compositions for modulating responsiveness to corticosteroids | |
| MX9602818A (es) | Un metodo de tratamiento de infeccion parasitaria usando antagonistas ige. | |
| DE69839992D1 (de) | Vorbeugende- oder Heilmittel zur Behandlung von Multipler Sklerose, mit antagonistischen anti-IL6-Rezeptor Antikörpern als Wirkstoff | |
| ATE301994T1 (de) | Verfahren zur erleichterung von schmerzen durch eine kombination von tramadol und einen nmda- antagonist | |
| DK1061929T3 (da) | Farmaceutisk præparat på basis af syntetisk naturligt progesteron og östradiol samt fremgangsmåde til fremstilling deraf | |
| DK0944396T3 (da) | Præparater og fremgangsmåder til forøgelse af tarmfunktion | |
| DK0873340T3 (da) | Heterocyklisk substituerede cyclopentanforbindelser | |
| TR200001218T2 (tr) | İkameli karboksamidotiazoller, bunların üretimi ve bunları içeren farmasötik bileşimler. | |
| FR2396417A1 (fr) | Composant semi-conducteur comprenant une resistance | |
| DK0839026T3 (da) | Micellære polyether-blokcopolymerkompositioner til målretning af biologiske midler | |
| Martinelli et al. | Utility of embolization or chemoembolization as second‐line treatment in patients with advanced or recurrent colorectal carcinoma | |
| ATE332919T1 (de) | Inhibitoren von phosphoserin- und phosphothreoninspezifischen isomerasen | |
| ES2171589T3 (es) | Composiciones farmaceuticas solidas anhidras para uso vaginal. | |
| AU1023497A (en) | Tissue factor - kunitz domain fusion proteins as factor viia inhibitors | |
| MX9101958A (es) | Inhibidores de acat de urea de aminosulfonilo | |
| ATE205074T1 (de) | Schminkgarnitur mit filmbildenden zusammensetzungen | |
| BR9503163A (pt) | Composição composições farmacêuticas procedimentos para obtenção de composição e para obtenção de quatro subcomposições primeira subcomposição segunda subcomposição terceira subcomposição quarta subcomposição e composição constituída por quatro subcomposições | |
| GEP20084346B (en) | Protein kinase c inhibitors | |
| DE69733752D1 (de) | Arzneimittel enthaltend oxaprozin natriumsalz, kaliumsalz, oder tris(hydroxymethyl)aminomethansalz | |
| BG100863A (en) | Fibrin-specifil antibody and its use as an antithrombotic agent | |
| Collins et al. | Factor Vila and other haemostatic variables following bone marrow transplantation | |
| DE69412940D1 (de) | Verfahren und zusammensetzung zur verminderung der effekte von endogener alkalischer phosphatase | |
| MA26540A1 (fr) | Composes nouveaux inhibiteurs de proteases et compositions pharmaceutiques les contenant. | |
| DE69431603T2 (de) | Oligopeptide hergeleitet von fragmenten des c-reaktiven proteins |